Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States

A comprehensive simulation of lifetime course of HIV in the USA indicated that using LPV/r as first-line therapy compared with DRV + RTV may result in cost savings, with similar clinical outcomes. </AbstractSection> Copyright Springer International Publishing Switzerland 2013

MoreLess

Year of publication:	2013
Authors:	Simpson, Kit ; Pei, Pamela ; Möller, Jörgen ; Baran, Robert ; Dietz, Birgitta ; Woodward, William ; Migliaccio-Walle, Kristen ; Caro, J.
Published in:	PharmacoEconomics. - Springer, ISSN 1170-7690. - Vol. 31.2013, 5, p. 427-444
Publisher:	Springer

More details

Extent:	text/html
Type of publication:	Article
Source:	RePEc - Research Papers in Economics

Persistent link: https://www.econbiz.de/10011001602